Insider Selling: Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Insider Sells $263,350.00 in Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) insider Helen Louise Collins sold 5,000 shares of the stock in a transaction on Friday, July 17th. The shares were sold at an average price of $52.67, for a total value of $263,350.00. Following the sale, the insider directly owned 25,000 shares in the company, valued at $1,316,750. This trade represents a 16.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Louise Collins also recently made the following trade(s):

• On Wednesday, June 17th, Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock. The stock was sold at an average price of $43.80, for a total value of $219,000.00.

Bitwise MARA Option Income Strategy ETF Trading Down 0.4%

NYSEARCA:IMRA traded down $0.06 during mid-day trading on Tuesday, reaching $14.46. The company’s stock had a trading volume of 890 shares, compared to its average volume of 4,858. The stock has a market cap of $1.88 million, a P/E ratio of 289.20 and a beta of 2.74. The firm’s fifty day moving average price is $16.56 and its two-hundred day moving average price is $15.49. Bitwise MARA Option Income Strategy ETF has a 12-month low of $11.99 and a 12-month high of $43.70.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.